{
    "id": 24228,
    "fullName": "LYN Y508F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "LYN Y508F lies within a phosphotyrosine residue in the Lyn protein (UniProt.org). Y508F results in constitutive activation of Lyn in cell culture and mouse models and leads to increased Bcl-2 expression in cultured cells, and is associated with drug resistance (PMID: 15175350, PMID: 11672542).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6296,
                    "pubMedId": 15175350,
                    "title": "A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15175350"
                },
                {
                    "id": 6297,
                    "pubMedId": 11672542,
                    "title": "Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11672542"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4067,
        "geneSymbol": "LYN",
        "terms": [
            "LYN",
            "JTK8",
            "p53Lyn",
            "p56Lyn"
        ]
    },
    "variant": "Y508F",
    "createDate": "07/12/2016",
    "updateDate": "06/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 159665,
        "transcript": "NM_002350",
        "gDna": "chr8:g.56010094A>T",
        "cDna": "c.1523A>T",
        "protein": "p.Y508F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7288,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7291,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7287,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7280,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of LYN Y508F conferred resistance to Gleevec (imatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 15175350).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6296,
                    "pubMedId": 15175350,
                    "title": "A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15175350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24958,
            "profileName": "LYN Y508F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24962,
            "profileName": "BCR - ABL1 LYN Y508F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 159665,
            "transcript": "NM_002350",
            "gDna": "chr8:g.56010094A>T",
            "cDna": "c.1523A>T",
            "protein": "p.Y508F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}